BioNTech Posts About 50% Drop In Q3 Sales and Profits Amid Falling Demand For COVID-19 Shots

  • BioNTech SE BNTX has reported Q3 FY22 revenues of €3.46 billion, down from €6.09 billion a year ago, blaming the dynamic course of the pandemic leading to fluctuations in quarterly revenues.
  • The company posted diluted EPS of €6.98, down from €12.35 a year ago.
  • The company has invoiced approximately 300 million doses of the original/omicron BA.1- and BA.4/BA.5-adapted bivalent vaccines as of mid-October 2022.
  • Ugur Sahin, BioNTech's co-founder & CEO, said, "The next chapter of BioNTech's evolution is becoming tangible; we continue to expand our COVID-19 vaccine and infectious disease portfolio and advance our oncology pipeline."
  • Related: BioNTech's COVID-19 Vaccine Becomes First Foreign Shot To Be Available In Chinese Market.
  • Outlook: BioNTech has raised its COVID-19 vaccine revenue estimate to the upper end of the original range: €16 - 17 billion (previously: €13 - 17 billion). 
  • The updated guidance reflects the shipment of the Omicron-adapted bivalent vaccine boosters, which started early in September and is expected to continue throughout the fourth quarter of 2022, as well as higher prices and a favorable foreign currency effect.
  • Price Action: BNTX shares are down 4.41% at $147.51 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CarePre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!